Inhibitory effects of phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: Evidence for CYP3A4 mechanism-based Inhibition

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 2, 2011, Pages 154-161

  Taesotikul, Theerada ^a   Dumrongsakulchai, Weeraya ^a   Wattanachai, Nitsupa ^a   Navinpipat, Vichien ^b   Somanabandhu, Aimon ^c   Tassaneeyakul, Wongwiwat ^d   Tassaneeyakul, Wichittra ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b Queen Sirikit Hospital   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d KHON KAEN UNIVERSITY   (Thailand)

Author keywords

CYP3A4; Cytochromes P450; Herb drug interaction; Hypophyllanthin; Mechanism based inhibitor; Phyllanthin; Phyllanthus amarus

Indexed keywords

ALCOHOL; CHLORZOXAZONE; CIMETIDINE; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; ERYTHROMYCIN; FLUOXETINE; FURAFYLLINE; HYPOPHYLLANTHIN; KETOCONAZOLE; LIGNAN DERIVATIVE; PAROXETINE; PHENACETIN; PHENYTOIN; PHYLLANTHIN; PHYLLANTHUS AMARUS EXTRACT; QUINIDINE; TESTOSTERONE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HERB DRUG INTERACTION; HUMAN; IC 50; LIVER MICROSOME; MALE; PHYLLANTHUS AMARUS; STEROID HYDROXYLATION;

EID: 79955711858     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RG-107     Document Type: Article

References (33)

1. Zhou, S. F.: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab., 9: 310-322 (2008).
2. Zhou, S. F., Xue, C. C., Yu, X. Q., Li, C. and Wang, G.: Clinically important drug interactions potentially involving mechanism- based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit., 29: 687-710 (2007).
3. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M. and McLeod, H. L.: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 44: 279-304 (2005).
4. Aueviriyavit, S., Kobayashi, K. and Chiba, K.: Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice. Drug Metab. Pharmacokinet., 25: 93-100 (2010).
5. Dresser, G. K., Spence, J. D. and Bailey, D. G.: Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet., 38: 41-57 (2000).
6. Tassaneeyakul, W., Guo, L.-Q., Fukuda, K., Ohta, T. and Yamazoe, Y.: Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch. Biochem. Biophys., 378: 356-363 (2000).
7. Iwata, H., Tezuka, Y., Kadota, S., Hiratsuka, A. and Watabe, T.: Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. Drug Metab. Pharmacokinet., 20: 34-45 (2005).
8. Usia, T., Watabe, T., Kadota, S. and Tezuka, Y.: Metabolitecytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci., 76: 2381-2391 (2005).
9. Usia, T., Watabe, T., Kadota, S. and Tezuka, Y.: Mechanismbased inhibition of CYP3A4 by constituents of Zingiber aromaticum. Biol. Pharm. Bull., 28: 495-499 (2005).
10. Tassaneeyakul, W., Tassaneeyakul, W., Vannaprasaht, S. and Yamazoe, Y.: Formation of omeprazole sulphone but not 5- hydroxyomeprazole is inhibited by grapefruit juice. Br. J. Clin. Pharmacol., 49: 139-144 (2000).
11. Bailey, D. G., Spence, J. D., Munoz, C. and Arnold, J. M. O.: Interaction of citrus juices with felodipine and nifedipine. Lancet, 337: 268-269 (1991).
12. Ducharme, M. P., Warbasse, L. H. and Edwards, D. J.: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther., 57: 485-491 (1995).
13. Calixto, J. B., Santos, A. R., Cechinel Filho, V. and Yunes, R. A.: A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential. Med. Res. Rev., 18: 225-258 (1998).
14. Kiemer, A. K., Hartung, T., Huber, C. and Vollmar, A. M.: Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-kappaB pathway. J. Hepatol., 38: 289-297 (2003).
15. Kassuya, C. A. L., Leite, D. F. P., de Melo, L. V., Rehder, V. L. G. and Calixto, J. B.: Anti-inflammatory properties of extracts, fractions and lignans isolated from Phyllanthus amarus. Planta Med., 71: 721-726 (2005).
16. Faremi, T. Y., Suru, S. M., Fafunso, M. A. and Obioha, U. E.: Hepatoprotective potentials of Phyllanthus amarus against ethanolinduced oxidative stress in rats. Food Chem. Toxicol., 46: 2658-2664 (2008).
17. Naaz, F., Javed, S. and Abdin, M. Z.: Hepatoprotective effect of ethanolic extract of Phyllanthus amarus Schum. et Thonn. on aflatoxin B1-induced liver damage in mice. J. Ethnopharmacol., 113: 503-509 (2007).
18. Notka, F., Meier, G. and Wagner, R.: Concerted inhibitory activities of Phyllanthus amarus on HIV replication in vitro and ex vivo. Antiviral Res., 64: 93-102 (2004).
19. Pramyothin, P., Ngamtin, C., Poungshompoo, S. and Chaichantipyuth, C.: Hepatoprotective activity of Phyllanthus amarus Schum. et. Thonn. extract in ethanol treated rats: in vitro and in vivo studies. J. Ethnopharmacol., 114: 169-173 (2007).
20. Krithika, R., Mohankumar, R., Verma, R. J., Shrivastav, P. S., Mohamad, I. L., Gunasekaran, P. and Narasimhan, S.: Isolation, characterization and antioxidative effect of phyllanthin against CCl4- induced toxicity in HepG2 cell line. Chem. Biol. Interact., 181: 351-358 (2009).
21. Chirdchupunseree, H. and Pramyothin, P.: Protective activity of phyllanthin in ethanol-treated primary culture of rat hepatocytes. J. Ethnopharmacol., 128: 172-176 (2010).
22. Murugaiyah, V. and Chan, K. L.: Antihyperuricemic lignans from the leaves of Phyllanthus niruri. Planta Med., 72: 1262-1267 (2006).
23. Appiah-Opong, R., Commandeur, J. N., Axson, C. and Vermeulen, N. P.: Interactions between cytochromes P450, glutathione S-transferases and Ghanaian medicinal plants. Food Chem. Toxicol., 46: 3598-3603 (2008).
24. Hari Kumar, K. B. and Kuttan, R.: Inhibition of drug metabolizing enzymes (cytochrome P450) in vitro as well as in vivo by Phyllanthus amarus SCHUM & THONN. Biol. Pharm. Bull., 29: 1310-1313(2006).
25. Tassaneeyakul, W., Birkett, D. J., McManus, M. E., Veronese, M. E., Andersson, T., Tukey, R. H. and Miners, J. O.: Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol., 47: 1767-1776 (1994).
26. Somanabandhu, A., Nitayangkura, S., Mahidol, C., Ruchirawat, S., Likhitwitayawuid, K., Shieh, H.-I., Chai, H., Pezzuto, J. M. and Cordell, G. A.: 1H- and 13C-NMR assignments of phyllanthin and hypophyllanthin: Lignans that enhance cytotoxic responses with cultured multidrug-resistant cells. J. Nat. Prod., 56: 233-239 (1993).
27. Guo, L. Q., Fukuda, K., Ohta, T. and Yamazoe, Y.: Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos., 28: 766-771 (2000).
28. Galetin, A., Gertz, M. and Houston, J. B.: Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab. Pharmacokinet., 25: 28-47 (2010).
29. Tassaneeyakul, W., Guo, L. Q., Fukuda, K., Ohta, T. and Yamazoe, Y.: Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch. Biochem. Biophys., 378: 356-363 (2000).
30. Tsunoda, S. M., Velez, R. L., von Moltke, L. L. and Greenblatt, D. J.: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther., 66: 461-471 (1999).
31. Wu, C. Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y. and Wacher, V. J.: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther., 58: 492-497 (1995).
32. Chaudhary, A. and Willett, K. L.: Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. Johnös wort. Toxicology, 217: 194-205 (2006).
33. Chen, Y., Xiao, P., Ou-Yang, D. S., Fan, L., Guo, D., Wang, Y. N., Han, Y., Tu, J. H., Zhou, G., Huang, Y. F. and Zhou, H. H.: Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin. Exp. Pharmacol. Physiol., 36: 828-833 (2009).